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High expression of DNA 
damage‑inducible transcript 
4 (DDIT4) is associated 
with advanced pathological 
features in the patients 
with colorectal cancer
Fahimeh Fattahi1,2, Leili Saeednejad Zanjani1, Zohreh Habibi Shams3, Jafar Kiani1,2, 
Mitra Mehrazma1,3, Mohammad Najafi4* & Zahra Madjd1,2,3*
DNA damage‑inducible transcript 4 (DDIT4) is induced in various cellular stress conditions. This study 
was conducted to investigate expression and prognostic significance of DDIT4 protein as a biomarker 
in the patients with colorectal cancer (CRC). PPI network and KEGG pathway analysis were applied 
to identify hub genes among obtained differentially expressed genes in CRC tissues from three GEO 
Series. In clinical, expression of DDIT4 as one of hub genes in three subcellular locations was evaluated 
in 198 CRC tissues using immunohistochemistry method on tissue microarrays. The association 
between DDIT4 expression and clinicopathological features as well as survival outcomes were 
analyzed. Results of bioinformatics analysis indicated 14 hub genes enriched in significant pathways 
according to KEGG pathways analysis among which DDIT4 was selected to evaluate CRC tissues. 
Overexpression of nuclear DDIT4 protein was found in CRC tissues compared to adjacent normal 
tissues (P = 0.003). Furthermore, higher nuclear expression of DDIT4 was found to be significantly 
associated with the reduced tumor differentiation and advanced TNM stages (all, P = 0.009). No 
significant association was observed between survival outcomes and nuclear expression of DDIT4 in 
CRC cases. Our findings indicated higher nuclear expression of DDIT4 was significantly associated with 
more aggressive tumor behavior and more advanced stage of disease in the patients with CRC.
Colorectal cancer (CRC) as a heterogeneous disease is considered as the second leading cause of cancer-related 
deaths  worldwide1. Molecular heterogeneity of CRC is due to genetic modifications commonly driving advance-
ment in cancer and development of the  disease2,3. Overall survival varies significantly in the patients with CRC 
depending on stage of the disease at the time of diagnosis and treatment  decisions4–6. Despite the recent advances 
in screening and treatment of CRC, there is still a need to identify new markers for early diagnosis and prognosis 
in order to improve treatment  decisions6. Therefore, diagnostic and prognostic biomarkers are required that could 
be more clinically applicable rather than conventional  biomarkers7 and stratify the patients with CRC for cancer 
 therapy6,8,9. In this regard, studying character and frequency of genetic and epigenetic alterations in cancer has 
been used as a great tool to investigate and identify those biomarkers which are linked to tumor development 
and medicine  arrangements3,9.
Omics technologies have been used in order to characterize molecular features of tumor cells and their func-
tional irregularities in cancer findings of which have been utilized in clinical settings to help cancer  treatment10. 
Bioinformatics and computational biology are also necessary for analysis of Omics data and discovering biomark-
ers that will become an important part of medical research as well as clinical  routine11. Therefore, in the present 
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study, bioinformatics tools were applied to identify hub genes among the differentially expressed genes (DEGs) 
influencing CRC from transcriptome data, which led to identification of DNA damage-inducible transcript 4 
(DDIT4) to investigate in CRC tissues as prognostic biomarker.
DDIT4 also known as a regulated in development and DNA damage response 1 (REDD1) protein and 
hypoxia-inducible factor 1 (HIF1)-responsive protein RTP801 (RTP801) was discovered and cloned in  200212,13. 
Generally, DDIT4 is rapidly induced in various cellular  stresses12,14, such as  hypoxia15,16, heat  shock17, endoplas-
mic reticulum stress, and chemical  molecules18. Most reports on DDIT4 function have indicated that DDIT4 
protein suppresses mammalian target of rapamycin complex 1 (mTORC1) and regulates cell growth, tumori-
genesis, cell aging, and  autophagy12,14,19–21.
Upregulation of DDIT4 has been shown to promote cell proliferation, reduce apoptotic rate, and S phase 
arrest in gastric epithelial  cells22. Moreover, upregulation of DDIT4 protein has been found to be associated with 
the decreased expression of pro-apoptotic proteins and at the same time the increased levels of anti-apoptotic 
proteins after inducing activity of RAS oncogene in ovarian epithelial  cells23,24.
Prominently, the previous studies have revealed that dysregulation of DDIT4 occurs in various human can-
cers with paradoxical roles. A number of studies have attributed DDIT4 to tumor suppressor process, through 
suppression of mTORC1 in CRC 25, breast  cancer26, sporadic clear cell renal cell carcinoma (ccRCC)27, and non-
small cell lung  cancer28. While as an oncogene, upregulation of DDIT4 contributes to reduction of apoptosis 
processes, promotion of proliferation, migration, and invasion of cancer cells in in-vitro and in-vivo cancer 
 studies22,29–31. High expression levels of DDIT4 protein have been observed in ovarian cancer (OC)31, bladder 
urothelial carcinoma (BUC)30, ccRCC (patients with von Hippel Lindau-deficient)27, and gastric cancer (GC)22 
tissues compared to adjacent normal tissues. Increased expression of DDIT4 has been remarked as a prognosis 
factor in the patients with OC and  BUC30–32. Additionally, DDIT4 gene is introduced as a cell intrinsic regulator 
for cancer therapy resistance in some cancers like brain, lung and gastric because it confers protection of tumor 
cells from  therapy19,22,33. In contrast, in CRC, therapy with baicalein and polyisoprenylated benzophenones as 
anticancer agents in in-vitro indicated upregulation of DDIT4 associated with growth  inhibition25,34.
In the present study, publicly available transcriptomic series (GSE74602, GSE110223, and GSE110224) were 
applied to detect genes that were differentially expressed in tumor tissues compared to adjacent normal tissues 
from the CRC patients. For identifying hub genes based on protein information, a protein–protein interaction 
(PPI) network was created for common upregulated DEGs among these three series. Then, Kyoto encyclope-
dia of genes and genomes (KEGG) pathway enrichment analysis was done in order to better understand the 
pathways in which hub genes are involved. The bioinformatics analysis and literature review of these hub genes 
led to selection of DDIT4 as a biomarker in CRC tissues. Besides, in our other study, we have evaluated and 
detected mRNA expression levels of DDIT4 as a predictor biomarker for advanced disease in fresh CRC tissue 
 samples35, herein, expression of DDIT4 protein was further confirmed as a biomarker in clinical CRC samples. 
Expression levels and localization of DDIT4 protein, for the first time were investigated in nucleus, cytoplasm, 
and plasma membrane for a series of formalin-fixed paraffin-embedded (FFPE) tissues from CRC patients 
using the immunohistochemistry (IHC) method on tissue microarrays (TMAs). Then, the associations between 
expression levels of DDIT4 protein at different subcellular locations with clinicopathological features as well as 
survival outcomes were analyzed.
Results
Bioinformatics approach. Identification of the upregulated DEGs and PPI network. The workflow of our 
research is presented in Fig. 1. Based on the preset criteria of log FC ≥  ± 1.0 and adjusted P value < 0.05, 1672 
DEGs (673 upregulated and 999 downregulated), 589 DEGs (245 upregulated and 344 downregulated), and 814 
DEGs (359 upregulated and 455 downregulated) were extracted from GSE74602, GSE110223, and GSE110224 
series, respectively, using volcano plots as shown in Fig. 2A–C. Further investigation of the obtained upregulated 
DEGs from three series using Venn diagram analysis displayed that there were 72 common upregulated DEGs 
between these series (Fig. 2D and Supplementary Table 1). Despite the most of DEGs in the current study were in 
line with our previous results in other CRC series of  GEO36, we rechecked 72 common upregulated DEGs from 
this analysis with obtained common DEGs of merged three series (GSE74602, GSE110223, and GSE110224) 
by MINT tool method (Supplementary Fig. S1 and Table S1). Comparison between these DEGs by MINT and 
72 common upregulated genes showed that total 72 common upregulated genes exist in common upregulated 
DEGs by MINT method.
For investigating all the protein interactions available for 72 common upregulated DEGs, a PPI network was 
constructed for these genes according to IMEX database, which included 3831 nodes and 9911 edges (Fig. 3A). 
Sixty-five genes with high connectivity degree were extracted from this network by cyto-Hubba in which 29 
genes overlapped with 72 common upregulated DEGs (Fig. 3B,C). Therefore, these 29 genes were considered as 
hub genes of common upregulated DEGs for subsequent analysis (Supplementary Table 1).
KEGG pathway and gene ontology (GO) analysis for hub genes. The KEGG pathway analysis for 29 hub genes 
indicated that these genes were involved and clustered in different pathways, such as ‘progesterone-mediated 
oocyte maturation’, ‘cell cycle’ and ‘PI3K-Akt signaling pathway’ as summarized in Fig.  4A. (Supplementary 
Table 2). Moreover, 14 hub genes were found in 10 pathway terms with P < 0.05 (Table 1) that GO enrichment 
analysis was performed in order to obtain more comprehensive and deep understanding of the biological pro-
cess and function of these hub genes. GO enrichment analysis in MF domain indicated that most 14 hub genes 
were clustered in functional groups of ‘protein binding’ and ‘cyclin-dependent protein kinase activity’ (Fig. 4B). 
These hub genes were mainly enriched in ‘histone phosphorylation’ and ‘response to drug’ groups of BP domain 
(Fig. 4C). Also, KEGG pathways involved in CRC diseases were obtained from the KEGG DISEASE Database, 
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which included ‘mucin type O-glycan biosynthesis’, ‘colorectal cancer pathway’, and ‘microRNAs in cancer’ path-
ways as summarized in Supplementary Fig. S2. Then, accurate scrutiny of hub genes҆ pathways displayed those 3 
hub genes (MET, DDIT4, and SERPINB5) were involved in ‘microRNAs in cancer’ pathway, a part of pathways 
in CRC diseases based on KEGG database. Finally, literature review and enrichment analysis led to selection 
of DDIT4 to evaluate protein expression level of this marker in CRC tissues. According to the KEGG pathway 
analysis, DDIT4 was found to be related to PI3k-Akt/mTOR signaling and microRNAs in cancer pathway, as a 
part of CRC disease using the KEGG DISEASE Database. PI3k-Akt/mTOR signaling is frequently deregulated in 
human cancer that is one of the primary mechanisms for sustaining tumor outgrowth and metastasis. Targeting 
these pathways have been considered as a strategy for cancer  therapy37,38. DDIT4 was participated in important 
BP and MF, such as cell death, response to drug, protein binding, and cellular response to stress in the cell. 
Moreover, our review of literature indicated that DDIT4 protein expression was not evaluated in CRC patients 
with various stages by IHC.
Subcellular localization study for DDIT4 showed that this marker is mostly enriched in the cytosol and cell 
nucleus and also to some extent; it is found in the plasma membrane and extracellular environment based on 
COMPARTMENTS database.
Findings related to the study population. Baseline characteristics of the study population. A total of 
198 samples from CRC population were included in the current study, in which 104 (52.5%) samples belonged 
to males and 94 (47.5%) of them were from females with a male/female ratio of 1.1. Mean age of the patients 
was equal to 59 (SD = 13) years old, (ranging from 25 to 88); 98 (49.5%) patients were younger than 59 and 100 
(50.5%) of them were over 59 years old. Tumor size, ranging from 1 to 24 cm was categorized based on mean 
size into two groups: Group 1: ≤ 5 cm [134 cases (67.7%)] and Group 2: > 5 cm [64 cases (32.3%)]. In this study, 
90 (45.5%) patients had well differentiated, 95 (48.0%) patients had moderately differentiated, and 13 (6.6%) of 
them had poorly differentiated. Moreover, 31 (15.7%) cases were at stage I of the disease, 81 (40.9%) cases were 
at stage II, 79 (39.9%) cases were at stage III, and 7 (3.5%) cases were at stage IV according to TNM stage system. 
Vascular and perineural invasion were observed in 33 (16.7%) and 48 (24.2%) of the patients with CRC, respec-
tively while lymph node metastasis was found in 84 (42.4%) cases.
Expression and localization of DDIT4 in CRC tissues. For estimating expression levels of DDIT4, three scoring 
systems were employed incorporating intensity of staining, percentage of positive tumor cells, and the H-score. 
Furthermore, expression of DDIT4 was detected at different subcellular locations including nucleus, cytoplasm, 
Figure 1.  The workflow of the present study. This flowchart is a schematic overview of the bioinformatics 
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and plasma membrane in both CRC tumor cells and adjacent normal tissues by IHC analysis. However, a sig-
nificant overexpression of DDIT4 at nucleus was observed in tumor cells compared to adjacent normal tissue 
samples (P = 0.003). This comparison was not statistically significant in terms of cytoplasmic and membranous 
expression of DDIT4. Measurement of staining based on the median H-score as the cut-off was done for lower 
DDIT4 expression versus higher DDIT4 expression in the nucleus, cytoplasm, and plasma membrane of cells. 
Expression of DDIT4 protein in CRC and adjacent normal tissue samples are exhibited in Fig. 5A–G1. Also, 
DDIT4 expression was observed with various intensities amongst the CRC tissues in various locations (Table 2).
Besides, human normal liver tissue as a positive control exhibited moderate staining in cytoplasm of all the 
hepatocyte and bile duct cells as well as nucleus of a few cells lining the sinusoids and results related to positive, 
negative, and isotype controls are shown in Fig. 5H–J.
Association between expressions of DDIT4 and clinicopathological features. Nuclear and cytoplasmic expres-
sions of DDIT4 were observed in all CRC samples while membranous expression of DDIT4 was not found in 2 
(1%) cases of total patients with CRC. In this study, Pearson’s chi-squared test was used to investigate the asso-
ciation between expression levels of DDIT4 and various clinicopathological features in the patients with CRC. 
The results of TMA-based IHC analysis were prepared according to the patients҆ clinicopathological features and 
are presented in Tables 3, 4, and 5 based on subcellular locations of DDIT4 marker staining. The results of Pear-
son’s chi-square test revealed that nuclear expression of DDIT4 in terms of intensity of staining (P = 0.031) and 
H-score (P = 0.009) had a significant association with tumor differentiation. In addition, a significant association 
was found between nuclear expression of DDIT4 and TNM stages (intensity of staining; (P = 0.013) and H-score 
[(P = 0.009), respectively]. The Spearman’s correlation test indicated a significant direct correlation between 
nuclear expression of DDIT4 with tumor differentiation and TNM stages (P < 0.05).
Figure 2.  Identification of the differentially expressed genes (DEGs) in tumor tissues compared to adjacent 
normal tissues. Volcano plots of the gene expression profile from the (A) GSE74602, (B) GSE110223, and (C) 
GSE110224 series. The red dots at the top right represent the upregulated DEGs and the blue dots at the top left 
represent the downregulated DEGs (log FC ≥  ± 1, adjusted P value < 0.05). (D) Venn diagram displayed common 
upregulated DEGs among three series for subsequent analysis.
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The data of the Kruskal–Wallis test exhibited statistically significant differences between the median nuclear 
expression level of DDIT4 and tumor differentiation groups as well as various TNM stages (I–IV) (P < 0.05). 
Mann–Whitney U test also showed a significant difference in median nuclear expression level of DDIT4 between 
well and moderately differentiated groups of tumor differentiation (P = 0.037) (Fig. 6A). Median nuclear expres-
sion level of DDIT4 was 225 in moderately differentiated and it was 200 in well differentiated. Moreover, the 
results of Mann–Whitney U test revealed a significant difference in median nuclear expression level of DDIT4 
between stage II and stage III (P = 0.026). Similarly, median nuclear expression level of DDIT4 was 225 for stage 
III and 200 in stage II (Fig. 6B). The analysis did not reveal any significant differences in the association between 
cytoplasmic and membranous expression of DDIT4 with clinicopathological features.
Figure 3.  Protein–protein interaction (PPI) analysis based on IMEX database for common upregulated DEGs 
and detection of hub genes. (A) The nodes represent genes and edges represent the interactions between genes. 
The red nodes signify 72 common upregulated DEGs that are in the interaction with each other and other 
genes (green nodes). (B) PPI network analysis revealed the genes with high connectivity degree (> 75 percentile 
for the genes with degree > 10) by cyto-Hubba plug-in using Cytoscape software. The dashed lines indicate 
the connection of genes that are not direct. (C) The genes with high connectivity degree that overlapped with 
common upregulated DEGs were extracted as hub genes by Venn diagram.
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Survival outcomes based on expression of DDIT4 in the patients with CRC . The follow-up data were available for 
112 out of 198 patients with CRC in this study. During the follow-up time, disease-related death was reported 
in 28 patients (14.1%), recurrence and metastasis happened in 29 (14.6%) and 28 (14.1%) patients, respectively, 
while 79 (39.9%) cases were absent for these two parameters. Median and mean follow-up time for these CRC 
patients were 34 months (Q1 = 21 and Q3 = 47) (ranging from 1 to 105 months) and 36 (SD = 24), respectively. 
Survival calculation was applied for disease-specific survival (DSS) and progression-free survival (PFS) terms. 
Kaplan–Meier survival analysis was implemented to compare survival (DSS and PFS) in two groups of the 
patients with CRC (high versus low nuclear expression of DDIT4 protein). Results of survival analysis showed 
no significant association between survival (DSS and PFS) and nuclear expression levels of DDIT4 (Log-rank 
test; DSS and PFS, P = 0.958, P = 0.911) (Fig. 7A,B).
Figure 4.  KEGG pathways and gene ontology (GO) analysis for hub genes in Cytoscape software by ClueGO 
plug-in. (A) KEGG pathway analysis for 29 obtained hub genes of protein–protein interaction network. (B) 
Gene ontology analysis for domains of molecular function (MF) and (C) biological process  (BP) for 14 hub 
genes involved in KEGG pathways with P value < 0.05.
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Discussion
Regarding study of cancer heterogeneity, biomarkers are valuable that can improve clinical management and the 
potential for recognition of therapeutic targets in drug development for CRC 39. In this regard, development of 
markers and multiple therapeutics has led to an increase in survival up to 3 years for the patients with CRC at 
advanced stages of disease that is still not  satisfactory40. For recognizing biomarkers in CRC, three series of the 
GEO were analyzed and common upregulated DEGs of these series were screened. Results of the PPI network and 
enrichment analyses determined hub genes that a few of them including DDIT4 were involved in ‘microRNAs 
in cancer’, a pathway in CRC disease based on the KEGG DISEASE Database. Moreover, KEGG pathway enrich-
ment analysis revealed that DDIT4 participates in PI3K-Akt/mTOR signaling pathways as important regulators 
for properties of pluripotent stem  cells41. These signaling pathways are responsible for various functions and 
biological processes in cell, such as proliferation, differentiation, and  migration42. It is noteworthy that the defect 
of PI3K-Akt/mTOR signaling pathways has been reported in development and advances of CRC 43. Our findings 
reviewing literature indicated protein expression of DDIT4 in CRC clinical samples has received much less atten-
tion. Also, a higher expression of DDIT4 in mRNA level was observed in fresh CRC tumors compared to adjacent 
normal tissue samples in our previous  study35. To the best of our knowledge, this study is the first to investigate 
of protein levels and clinical significance of DDIT4 in the patients with CRC by TMA-based IHC method.
DDIT4 is an attractive potential target for therapeutic approach in  cancer12 silencing of which leads to sen-
sitization of tumor cells to cancer treatment and drugs in in-vitro and in-vivo  studies19,22,30,33. Inconsistent roles 
have been reported for DDIT4 in cell death and carcinogenesis so that, upregulated expression of DDIT4 occurs 
due to DNA-damaging agents via nuclear p53 manner that inhibits  mTORC144,45 and as a result can increase cell 
 death21,44. On the other hand, high expression of DDIT4 can protect human cancer cells from hypoxia-induced 
cell  death19,46,47 through stabilizing HIF1α in downstream of the suppressed mTOR pathway which followed 
by occurs increased cell survival and tumor  growth47. Moreover, studies have indicated a relationship between 
expression of DDIT4 and an increase in expression of BCL2 as anti-apoptotic protein and also changes in p53 
phosphorylation reducing  apoptosis12,22.
In-silico findings have shown high expression of DDIT4 in several cancers that is significantly associated with 
a worse  prognosis48. Our results using three GEO series illustrated the upregulated expression of DDIT4 in CRC 
tissues compared to adjacent normal tissues, corroborating with the previous study that indicated overexpression 
of DDIT4 as prognosis biomarker in the patients with CRC using bioinformatics  tools49. For further considering 
this marker, expression level of DDIT4 protein was investigated in 198 tissue samples from patients after surgery. 
Expression levels of DDIT4 were noticed in nucleus, cytoplasm, and plasma membrane substantiating the evi-
dence in the  literature31,50,51, and COMPARTMENTS database. Previous results have demonstrated localization 
of DDIT4 in nucleus and cytoplasm of the cells before activation while its translocation to plasma membrane 
was observed during activation and probably, it becomes disabled by this  mechanism51.
The evaluation of DDIT4 staining was obtained for each subcellular location in cells in a series of CRC tis-
sues with a range of intensities from weak to strong. Our analysis showed a statistically higher nuclear expres-
sion of DDIT4 compared to adjacent normal tissues in CRC, which is in line with the study by Chang et al. 
that observed high nuclear expression of DDIT4 in OC tissues compared to normal  tissues31. This result also 
validates the finding of a previous experiment that identified higher levels of DDIT4 protein in 10 CRC tissues 
compared to adjacent normal tissues by the western blot  method47. In addition, results of the population study 
confirmed and supported upregulation of DDIT4 expression in our bioinformatics analysis. We observed positive 
correlates of nuclear DDIT4 expression with the TNM stages and tumor differentiation. Notably, TNM staging 
and tumor differentiation are generally considered as traditional and important prognostic factors advance in 
which is associated with worse outcome for the patients with CRC 4,52–54. Generally, in solid tumors, an imma-
ture tumor is more aggressive than a tumor with a differentiated cell  phenotype55. Interestingly, median nuclear 
expression of DDIT4 was significantly higher in more advanced stage (stage III) compared to stage II, showing 
the association of nuclear expression of DDIT4 protein with aggressiveness of CRC. In addition, a significant 
association was found between the increased expression of DDIT4 and the decreased tumor differentiation so 
that, the patients with CRC who had moderately differentiated tumor cells showed higher nuclear expression 
of DDIT4 rather than cases with well differentiated tumor cells. This result is in line with the study by Chen 
Table 1.  Hub genes involved in pathways with P value < 0.05 based on KEGG pathway analysis.
KEGG number KEGG pathways Gene names P value
KEGG:04914 Progesterone-mediated oocyte maturation AURKA, CCNA2, CCNB1, CDK1, MAD2L1 < 0.00001
KEGG:04110 Cell cycle CCNA2, CCNB1, CDK1, MAD2L1 < 0.001
KEGG:04114 Oocyte meiosis AURKA, CCNB1, CDK1, MAD2L1 < 0.001
KEGG:04218 Cellular senescence CCNA2, CCNB1, CDK1, FOXM1 < 0.001
KEGG:04115 P53 signaling pathway CCNB1, CDK1, SERPINB5 < 0.001
KEGG:00240 Pyrimidine metabolism CTPS1, NME1 < 0.01
KEGG:04152 AMPK signaling pathway CCNA2, SCD 0.035
KEGG:05206 MicroRNAs in cancer DDIT4, MET, SERPINB5 0.040
KEGG:04151 PI3K-Akt signaling pathway COL1A1, DDIT4, MET 0.045
KEGG:00670 One carbon pool by folate SHMT2 0.048
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et al. that showed overexpression of DDIT4 may maintain seminomas in an undifferentiated  state56. Further-
more, there was no significant association between cytoplasmic and membranous expression of DDIT4 with 
clinicopathological features. Therefore, our results suggested that nuclear expression of DDIT4, rather than its 
cytoplasmic or membranous expression is related to advances of malignancy and progression in CRC. There 
was no significant association between expression of DDIT4 and survival in the patients with CRC, which is 
consistent with earlier findings on  GC22 but is contrary to the previous published studies on  OC31,32. Given that 
Figure 5.  Immunohistochemical analysis of DDIT4 expression in colorectal cancer (CRC) samples. Nuclear 
expression of DDIT4 in CRC: (A, A-1) low expression and (B, B-1) high expression. Cytoplasmic expression of 
DDIT4 in CRC: (C, C-1) low expression and (D, D-1) high expression. Membranous expression of DDIT4 in 
CRC: (E, E1) low expression and (F, F1) high expression. (G, G1) DDIT4 expression in adjacent normal tissue. 
(H) DDIT4 expression in normal human liver as a positive control, (I) DDIT4 expression in normal human liver 
as a negative control, and (J) Isotype control. (Figures shown with magnification of 100 × and 200 ×).
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our findings are based on follow-up time, it can be mentioned that a long-term follow-up may plausibly alter 
prognostic value of DDIT4 expression.
In CRC samples, more strong intensity and higher median expression of DDIT4 in nuclear staining for tumor 
tissues might be due to the role of DDIT4 in the cancer cells̓ nucleus. It has been proposed that DDIT4 may have 
different functions in subcellular  localization31,50; nevertheless, little information exists about nuclear expression 
of DDIT4. Despite several questions regarding DDIT4 functions in different cell locations, DDIT4 is a key player 
within the mTOR pathway that is critical for the cells. It is important to note that inhibition of mTOR pathway 
leads to the increased expression of cancer stem cell (CSC) markers and CSC  populations57, CSCs are a rare 
subpopulation of cancer cells within tumors with stemness, self-renewal, quiescence, and tumorigenicity proper-
ties that are resistant to cancer  therapy58,59. Studies have indicated that expression of DDIT4 promotes stemness 
markers and is related to features of  CSC60–62. Drug resistance and therapeutic failure of tumor cells seems to be 
closely related to various properties and indispensable functions of CSCs, such as quiescence, overexpression of 
anti-apoptotic proteins, and the ability of DNA  repair63,64.
In conclusion, findings of this study highlighted overexpression of DDIT4 as a biomarker in CRC tissues 
especially in nucleus of tumor cells. Overexpression of DDIT4 protein may indicate more aggressive tumor 
behavior and more advanced disease in the patients with CRC. Although, nuclear expression of this marker has 
been observed in other tumors, function of the nuclear expression of DDIT4 protein has not been reported in 
the literature. Accordingly, evidence indicates that DDIT4 is a potential therapeutic marker. Therefore, there is 
a need to increase the knowledge regarding the role of DDIT4 in cell proliferation pathways and progression of 
cancer that may lead to improvement of prognosis and developing agents for targeted treatment.
Methods
Bioinformatics analysis. Microarray data source and screening for differentially expressed genes 
(DEGs). Data source. Primary search was performed on the Gene Expression Omnibus (GEO)  database65 
of the National Center for Biotechnology Information (NCBI) using keywords of "Colorectal Neoplasms" OR 
"Colorectal Cancer" OR "Colorectal Tumor" as search terms. Obtained GEO series of primary search were lim-
ited to expression profiling by array, homo sapiens, tissues, and publication dates [1 year (OCT 2018–2019)]. 
The samples and experiments҆ condition of series were closely checked in order to minimize heterogeneity for 
selection of expression profiles. Also, the last series of colon cancer without time limitation was added because 
colon cancer is more common than rectal  cancer1. Finally, three gene expression series including –GSE74602, 
GSE110223, and GSE110224—were selected from the GEO. Among series, GSE74602 had used 30 tumors 
and 30 adjacent normal colon samples based on the Agilent GPL6104 platform (Illumina humanRef-8 v2.0 
expression beadchip). GSE110223 was based on GPL96 platform ([HG-U133A] Affymetrix Human Genome 
U133A Array) that included 13 CRC tumors and 13 adjacent normal samples. While GSE110224 consisted of 17 
CRC tumors and 17 adjacent normal samples with GPL570 platform ([HG-U133_Plus_2] Affymetrix Human 
Genome U133 Plus 2.0 Array).
Identification of DEGs. The classification of CRC samples for our analysis was only based on their tumor 
and adjacent normal tissues, because our CRC patients in the population study section was lacking molecular 
subtypes of CRC. Expression of the genes was compared between tumors and adjacent normal tissues using the 
GEO2R online analysis tool (http:// www. ncbi. nlm. nih. gov/ geo/ geo2r) for each series. The DEGs in CRC tissues 
Table 2.  Nuclear, cytoplasmic, and membranous DDIT4 expression in colorectal cancer (CRC) tissues and 
their adjacent normal tissue samples (Intensity of staining, percentage of positive tumor cells, and H-score). P 













N (%) P value
Intensity of stain-
ing 0.004 0.023 0.013
No staining (0) 0 (0.0) 1 (2.6) 0 (0.0) 0 (0.0) 2 (1.0) 0 (0.0)
Weak (+ 1) 6 (3.0) 1 (2.6) 12 (6.1) 7 (17.9) 6 (3.0) 2 (5.1)
Moderate (+ 2) 86 (43.4) 26 (66.7) 134 (67.7) 26 (66.7) 101 (51.0) 28 (71.8)
Strong (+ 3) 106 (53.5) 11 (28.1) 52 (26.2) 6 (15.4) 89 (45.0) 9 (23.1)
Percentage of posi-
tive tumor cells 0.781 0.533 0.086
< 25% 1 (0.5) 1 (2.6) 0 (0.0) 0 (0.0) 4 (2.0) 0 (0.0)
25–50% 4 (2.0) 1 (2.6) 6 (3.0) 3 (7.7) 7 (3.5) 1 (2.6)
51–75% 53 (26.8) 10 (25.6) 73 (36.9) 14 (35.9) 69 (34.8) 9 (23.1)
> 75% 140 (70.7) 27 (69.2) 119 (60.1) 22 (56.4) 118 (59.6) 29 (74.4)
H-score cut off 0.003 0.142 0.211
Low 93 (47.0) 22 (56.4) 120 (60.6) 25 (64.1) 115 (58.1) 31 (79.5)
High 105 (53.0) 17 (43.6) 78 (39.4) 14 (35.9) 83 (41.9) 8 (20.5)
Total 198 39 198 39 198 39
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base cut-off criteria (logFC ≥  ± 1.0 and adjusted P value < 0.05) of each series were obtained and visualized by 
volcano plot using OriginPro 2019 (OriginLab Corporation, Northampton, MA, USA). Common upregulated 
DEGs in CRC tissues were extracted from three series for subsequent analysis by Venn diagram analysis in Orig-
inPro 2019 software. In order to recheck the common upregulated genes obtained in this method, the results 
were compared with common DEGs obtained by MINT method. MINT is a powerful approach to solve the 
integrative classification framework by combining multiple independent studies and is a part of the mixOmics 
R CRAN  package66. Therefore, 3 series of GEO were merged and detected common DEGs for them by MINT 
method in R platform.
Generation of PPI network and extraction of hub genes. PPI network. For finding more data about common 
upregulated DEGs and their interactions with other proteins in cellular activities, PPI network construction 
Table 3.  The association between nuclear DDIT4 expression and clinicopathological features of colorectal 
cancer (CRC) samples (Intensity of staining and H-score). P value; Pearson’s χ2 test, and Values in bold are 







Intensity of staining N (%)
P value
H-score (cut off = 210) 
N (%)
P value0 (Negative) 1+ (Weak)
2+ 




years (Range) 59 (25–88) 0.991 0.769
≤ Mean age 98 (49.5) 0 (0.0) 3 (50.0) 43 (50.0) 52 (49.1) 45 (48.4) 53 (50.5)
> Mean age 100 (50.5) 0 (0.0) 3 (50.0) 43 (50.0) 54 (50.9) 48 (51.6) 52 (49.5)
Gender 0.760 0.966
Male 104 (52.5) 0 (0.0) 4 (66.7) 44 (51.2) 56 (52.8) 49 (52.7) 55 (52.4)
Female 94 (47.5) 0 (0.0) 2 (33.3) 42 (48.8) 50 (47.2) 44 (47.3) 50 (47.6)
(Male/Female) 1.1 - 2 1.0 1.1 1.1 1.1
Mean tumor 
size (cm) 5 0.159 0.985
≤ Mean 134 (67.7) 0 (0.0) 2 (33.3) 61 (70.9) 71 (67.0) 63 (67.7) 71 (67.6)
> Mean 64 (32.3) 0 (0.0) 4 (66.7) 25 (29.1) 35 (33.0) 30 (32.3) 34 (32.4)
Tumor dif-
ferentiation 0.031 0.009
Well 90 (45.5) 0 (0.0) 2 (33.3) 50 (58.1) 38 (35.8) 53 (57.0) 37 (35.2)
Moderately 95 (48.0) 0 (0.0) 4 (66.7) 31 (36.0) 60 (56.6) 35 (37.6) 60 (57.1)
Poorly 13 (6.6) 0 (0.0) 0 (0.0) 5 (5.8) 8 (7.5) 5 (5.4) 8 (7.6)
TNM stages 0.013 0.009
I 31 (15.7) 0 (0.0) 0 (0.0) 10 (11.6) 21 (19.8) 11 (11.8) 20 (19.0)
II 81 (40.9) 0 (0.0) 3 (50.0) 46 (53.5) 32 (30.2) 48 (51.6) 33 (31.4)
III 79 (39.9) 0 (0.0) 3 (50.0) 25 (29.1) 51 (48.1) 29 (31.2) 50 (47.6)
IV 7 (3.5) 0 (0.0) 0 (0.0) 5 (5.8) 2 (1.9) 5 (5.4) 2 (1.9)
Vascular inva-
sion (VI) 0.874 0.848
Present 33 (16.7) 0 (0.0) 1(16.7) 13 (15.1) 19 (17.9) 15 (16.1) 18 (17.1)
Absent 165 (83.3) 0 (0.0) 5 (83.3) 73 (84.9) 87 (82.1) 78 (83.9) 87 (82.9)
Lymph node 
invasion (LNI) 0.343 0.199
Involved 84 (42.4) 0 (0.0) 2 (33.3) 32 (37.2) 50 (47.2) 35 (37.6) 49 (46.7)
None 114 (57.6) 0 (0.0) 4 (66.7) 54 (62.8) 56 (52.8) 58 (62.4) 56 (53.3)
Perineural 
invasion (PI) 0.314 0.629
Involved 48 (24.2) 0 (0.0) 3 (50.0) 21 (24.4) 24 (22.6) 24 (25.8) 24 (22.9)
None 150 (75.8) 0 (0.0) 3 (50.0) 65 (75.6) 82 (77.4) 69 (74.2) 81 (77.1)
Distant metas-
tasis 0.500 0.989
Present 28 (14.1) 0 (0.0) 0 (0.0) 11 (25.6) 17 (26.2) 12 (25.0) 16 (25.0)
Absent 84 (42.4) 0 (0.0) 4 (100.0) 32 (74.4) 48 (73.8) 36 (75.0) 48 (75.0)
Tumor recur-
rence 0.381 0.533
Yes 29 (14.6) 0 (0.0) 0 (0.0) 10 (23.3) 19 (29.2) 11 (22.9) 18 (28.1)
No 83 (41.9) 0 (0.0) 4 (100.0) 33 (76.7) 46 (70.8) 37 (77.1) 46 (71.9)
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was performed using the International Molecular Exchange Consortium (IMEx) in Cytoscape  software67. IMEx 
includes some databases, such as IntAct, DIP, HPIDB, MINT, and UniProtKB/Swiss-Prot without redundant set 
of interactions checking data quality and ensuring consistency between all the  series68.
Hub genes. The genes with high connectivity degree (> 75 percentile for genes with degree > 10) were selected 
from PPI network in Cytoscape software by cyto-Hubba plug-in69. Among the obtained genes with high con-
nectivity degree for this network, only the genes belonging to our common upregulated DEGs were selected as 
hub genes by Venn diagram.
Pathway and functional enrichment analysis for hub genes. The KEGG pathway analysis for all the hub genes 
was done in order to scrutinize the biological pathways in which these genes are involved. Then, gene ontology 
Table 4.  The association between cytoplasmic DDIT4 expression and clinicopathological features of colorectal 
cancer (CRC) samples (Intensity of staining and H-score). P value; Pearson’s χ2 test, and Values in bold are 







Intensity of staining N (%)
P value
H-score (cut off = 180) 
N(%)
P value0 (Negative) 1+ (Weak)
2+ 




years (Range) 59 (25–88) 0.187 0.640
≤ Mean age 98 (49.5) 0 (0.0) 8 (66.7) 69 (51.5) 21 (40.4) 61 (50.8) 37 (47.4)
> Mean age 100 (50.5) 0 (0.0) 4 (33.3) 65 (48.5) 31 (59.6) 59 (49.2) 41 (52.6)
Gender 0.557 0.377
Male 104 (52.5) 0 (0.0) 8 (66.7) 68 (50.7) 28 (53.8) 60 (50.0) 44 (56.4)
Female 94 (47.5) 0 (0.0) 4 (33.3) 66 (49.3) 24 (46.2) 60 (50.0) 34 (43.6)
(Male/Female) 1.1 - 2.0 1.0 1.1 1.0 1.2
Mean tumor 
size (cm) 5 0.679 0.578
≤ Mean 134 (67.7) 0 (0.0) 9 (75.0) 92 (68.7) 33 (63.5) 83 (69.2) 51 (65.4)
> Mean 64 (32.3) 0 (0.0) 3 (25.0) 42 (31.3) 19 (36.5) 37 (30.8) 27 (34.6)
Tumor dif-
ferentiation 0.554 0.987
Well 90 (45.5) 0 (0.0) 8 (66.7) 60 (44.8) 22 (42.3) 54 (45.0) 36 (46.2)
Moderately 95 (48.0) 0 (0.0) 4 (33.3) 64 (47.8) 27 (51.9) 58 (48.3) 37 (47.4)
Poorly 13 (6.6) 0 (0.0) 0 (0.0) 10 (7.5) 3 (5.8) 8 (6.7) 5 (6.4)
TNM stages 0.0466 0.375
I 31 (15.7) 0 (0.0) 2 (16.7) 21 (15.7) 8 (15.4) 15 (12.5) 16 (20.5)
II 81 (40.9) 0 (0.0) 5 (41.7) 60 (44.8) 16 (30.8) 53 (44.2) 28 (35.9)
III 79 (39.9) 0 (0.0) 5 (41.7) 47 (35.1) 27 (51.9) 47 (39.2) 32 (41.0)
IV 7 (3.5) 0 (0.0) 0 (0.0) 6 (4.5) 1 (1.9) 5 (4.2) 2 (2.6)
Vascular inva-
sion (VI) 0.207 0.696
Present 33 (16.7) 0 (0.0) 3 (25.0) 18 (13.4) 12 (23.1) 21 (17.5) 12 (15.4)
Absent 165 (83.3) 0 (0.0) 9 (75.0) 116 (86.6) 40 (76.9) 99 (82.5) 66 (84.6)
Lymph node 
invasion (LNI) 0.106 0.979
Involved 84 (42.4) 0 (0.0) 6 (50.0) 50 (37.3) 28 (53.8) 51 (42.5) 33 (42.3)
None 114 (57.6) 0 (0.0) 6 (50.0) 84 (62.7) 24 (46.2) 69 (57.5) 45 (57.7)
Perineural 
invasion (PI) 0.818 0.517
Involved 48 (24.2) 0 (0.0) 2 (16.7) 33 (24.6) 13 (25.0) 31 (25.8) 17 (21.8)
None 150 (75.8) 0 (0.0) 10 (83.3) 101 (75.4) 39 (75.0) 89 (74.2) 61 (78.2)
Distant metas-
tasis 0.976 0.912
Present 28 (14.1) 0 (0.0) 2 (22.2) 18 (25.0) 8 (25.8) 16 (24.6) 12 (25.5)
Absent 84 (42.4) 0 (0.0) 7 (77.8) 54 (75.0) 23 (74.2) 49 (75.4) 35 (74.5)
Tumor recur-
rence 0.736 0.717
Yes 29 (14.6) 0 (0.0) 3 (33.3) 17 (23.6) 9 (29.0) 16 (24.6) 13 (27.7)
No 83 (41.9) 0 (0.0) 6 (66.7) 55 (76.4) 22 (71.0) 49 (75.4) 34 (72.3)
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(GO) term enrichment analysis was performed in domains of molecular function (MF) and biological pro-
cess (BP) only for the hub genes involved in pathways with P value < 0.05. Moreover, pathways similar to those 
mentioned in CRC disease according to the KEGG DISEASE Database were considered in order to select a 
 biomarker70. These analyses were performed in Cytoscape software using ClueGO plug-in assisting the GO/
pathway analysis and visualizing functionally grouped terms in networks and  graphs71. Finally, one hub gene 
was selected for evaluation of protein expression levels using the IHC method in CRC tissue samples. Subcellular 
localization of this maker was investigated in COMPARTMENTS  database72.
Population study. Collection of tissue samples and TMA construction. Patients. FFPE blocks as well as 
hematoxylin and eosin (H&E)-stained slides of 198 CRC and 39 adjacent normal tissues from patients that had 
undergone tumor resection were included in this study. These samples were collected from three university 
Table 5.  The association between membranous DDIT4 expression and clinicopathological features of 
colorectal cancer (CRC) samples (Intensity of staining and H-score). P value; Pearson’s χ2 test, and Values in 







Intensity of staining N (%)
P value
H-score (cut off = 200) 
N(%)
P value0 (Negative) 1+ (Weak)
2+ 




years (Range) 59 (25–88) 0.328 0.143
≤ Mean age 98 (49.5) 0 (0.0) 4 (66.7) 53 (52.5) 41 (46.1) 62 (53.9) 36 (43.4)
> Mean age 100 (50.5) 2 (100.0) 2 (33.3) 48 (47.5) 48 (53.9) 53 (46.1) 47 (56.6)
Gender 0.781 0.686
Male 104 (52.5) 1 (50.0) 4 (66.7) 50 (49.5) 49 (55.1) 59 (51.3) 45 (54.2)
Female 94 (47.5) 1 (50.0) 2 (33.3) 51 (50.5) 40 (44.9) 56 (48.7) 38 (45.8)
(Male/Female) 1.1 1.0 2.0 0.9 1.2 1.0 1.1
Mean tumor 
size (cm) 5 0.674 0.958
≤ Mean 134 (67.7) 1 (50.0) 3 (50.0) 71 (70.3) 59 (66.3) 78 (67.8) 56 (67.5)
> Mean 64 (32.3) 1 (50.0) 3 (50.0) 30 (29.7) 30 (33.7) 37 (32.2) 27 (32.5)
Tumor dif-
ferentiation 0.198 0.817
Well 90 (45.5) 1 (50.0) 4 (66.7) 47 (46.5) 38 (42.7) 54 (47.0) 36 (43.4)
Moderately 95 (48.0) 0 (0.0) 2 (33.3) 47 (46.5) 46 (51.7) 53 (46.1) 42 (50.6)
Poorly 13 (6.6) 1 (50.0) 0 (0.0) 7 (6.9) 5 (5.6) 8 (7.0) 5 (6.0)
TNM stages 0.927 0.989
I 31 (15.7) 0 (0.0) 1 (16.7) 17 (16.8) 13(14.6) 18 (15.7) 13 (15.7)
II 81 (40.9) 0 (0.0) 3 (50.0) 40 (39.6) 38(42.7) 46 (40.0) 35 (42.2)
III 79 (39.9) 2 (100.0) 2 (33.3) 40 (39.6) 35(39.3) 47 (40.9) 32 (38.6)
IV 7 (3.5) 0 (0.0) 0 (0.0) 4 (4.0) 3(3.4) 4 (3.5) 3 (3.6)
Vascular inva-
sion (VI) 0.634 0.941
Present 33 (16.7) 0 (0.0) 0 (0.0) 17 (16.8) 16 (18.0) 19 (16.5) 14 (16.9)
Absent 165 (83.3) 2 (100.0) 6 (100.0) 84 (83.2) 73 (82.0) 96 (83.5) 69 (83.1)
Lymph node 
invasion (LNI) 0.400 0.724
Involved 84 (42.4) 2 (0.0) 2 (33.3) 43 (42.6) 37 (41.6) 50 (43.5) 34 (41.0)
None 114 (57.6) 0 (0.0) 4 (66.7) 58 (57.4) 52 (58.4) 65 (56.5) 49 (59.0)
Perineural 
invasion (PI) 0.647 0.294
Involved 48 (24.2) 1 (50.0) 1 (16.7) 27 (26.7) 19 (21.3) 31 (27.0) 17 (20.5)
None 150 (75.8) 1 (50.0) 5 (83.3) 74 (73.3) 70 (78.7) 84 (73.0) 66 (79.5)
Distant metas-
tasis 0.878 0.912
Present 28 (14.1) 0 (0.0) 1 (25.0) 14 (25.5) 13 (25.5) 16 (25.4) 12 (24.5)
Absent 84 (42.4) 2 (100.0) 3 (75.0) 41 (74.5) 38 (74.5) 47 (74.6) 37 (75.5)
Tumor recur-
rence 0.759 0.568
Yes 29 (14.6) 0 (0.0) 1 (25.0) 13 (23.6) 15 (29.4) 15 (23.8) 14 (28.6)
No 83 (41.9) 2 (100.0) 3 (75.0) 42 (76.4) 36 (70.6) 48 (76.2) 35 (71.4)
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hospitals-Hashemi Nejad, Firoozgar, and Hazrate Rasoole Akram in Tehran, Iran during 2012–2018. Patients 
had not received any relevant radiotherapy, chemotherapy, or immunotherapy before surgery. Clinicopatho-
logical features including age, gender, tumor size, tumor differentiation, TNM stage, vascular invasion (VI), 
lymph node invasion (LNI), perineural invasion (PI), distant metastasis, and tumor recurrence were obtained 
by reviewing clinicopathological records for each sample defined according to the American Joint Committee 
on Cancer (AJCC) in  201852.
Outcome information of the patients after surgery was also recorded. Disease-specific survival (DSS) was 
described as the time from initial surgery to the date of CRC-related death. Progression-free survival (PFS) was 
determined as the time between the primary surgery and the last follow-up interview if the patient with CRC 
displayed no evidence of disease, recurrence, or metastasis.
TMA construction. TMA blocks were provided as described  previously73. In brief, the most representative 
areas of the tumor and normal cells in different parts of tissue samples were selected by checking H&E slides. 
Then, a core of 0.6 mm diameter was separated from the selected areas in each donor block and was transferred 
to a new recipient paraffin block using a precision arraying instrument (Tissue Arrayer Minicore; ALPHELYS, 
Plaisir, France). In the current study, 3 cores of the selected areas randomly from each tissue sample were trans-
ferred and scored individually. These TMA blocks were built of different cores for each sample. TMA slides 
were obtained by cutting sections of TMA blocks, to a thickness of about 4 μm, which were transferred to an 
adhesive-coated slide system (SuperFrost Plus, Thermo Scientific™, Germany). Mean expression of 3 cores was 
calculated from each tissue sample in order to increase accuracy and validity of the data analysis. The TMA-
based IHC method is robust with respect to sampling that could increase this accuracy similar to conventional 
tissue sections, even analysis of 2 cores increased accuracy by more than 95%74,75.
Applying IHC method on TMA slides and immunostaining system scoring. IHC procedure. Immunostain-
ing of TMA sections for DDIT4 was performed as described  previously76. The slides were deparaffinized after 
30 min at 60 °C and were rehydrated in xylene and serial ethanol dilutions, respectively.  H2O2 (3%) was used for 
Figure 6.  Box plot analysis of DDIT4 expression levels in tumor differentiation groups and TNM stages. The 
bold line precisely represents median expression levels of DDIT4. (A) The result of data analysis showed a 
statistically significant association in the median nuclear expression of DDIT4 between well and moderately 
tumor differentiation (P = 0.037). (B) A statistically significant association was observed in the median nuclear 
expression of DDIT4 between stages II and III (P = 0.026).
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blockage of endogenous peroxidase on tissue sections for 20 min at room temperature. Following three times 
washing the tissue sections, antigen retrieval was carried out by covering the tissues in citrate buffer (pH 6.0) for 
10 min in an autoclave. Subsequently, tissue sections with primary antibody specific for DDIT4 (1:80 dilution, 
Biorbyt, Cambridge, UK) were incubated overnight at 4 °C. Furthermore, rabbit immunoglobulin IgG (Invit-
rogen, Thermo Fisher Scientific, Waltham, MA, USA) was applied at a dilution of 1:500 for isotype control test. 
For visualizing bound antibody-antigen, TMA slides were incubated with the secondary antibody (EnVision Kit, 
Dako, Glostrup, Denmark) for 30 min and then 3, 30-diaminobenzidine as chromogen (DAB, Dako, Glostrup, 
Denmark). The hematoxylin (Dako, Glostrup, Denmark) was used a counterstain for all the slides. Finally, the 
tissues slides were dehydrated in alcohol, and were cleared in xylenes until scoring by pathologists. The normal 
liver tissue was applied as positive control while Tris-buffered saline (TBS) was replaced by the primary antibody 
as the negative control per each run of the test.
Evaluation of immunostaining. Positive cells for staining of DDIT4 were assessed using a semi-quantitative 
scoring at 40X magnifications by two pathologists (Z.HS. and M.M.) who were blinded to pathological param-
eters and the patients҆ outcomes. DDIT4 staining intensity was scored in a 4-point scale (staining intensity scores: 
Figure 7.  Kaplan–Meier survival analysis according to nuclear expression levels of DDIT4 protein in colorectal 
cancer (CRC). Log-rank test did not show any significant difference in (A) DSS and (B) PFS between two groups 
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absent: 0, weak: 1, moderate: 2, or strong: 3) and percentage was estimated according to < 25, 25–50%, 51–75%, 
and > 75% of positive tumor cells. In calculation of the scores, H-score was obtained for each core through mul-
tiplying the intensity score by percentage of the stained cells ranging from 0 to  30077. The final H-scores were 
calculated from average of three score spots for each sample and were classified into two groups (low or high 
expression) according to median expression of DDIT4.
Statistical analysis. The Chi-square and Spearman’s correlation tests were used to analyze the association and 
correlation between expression of DDIT4 and clinicopathological features. The Kruskal–Wallis and Mann–
Whitney U tests were applied for comparison of DDIT4 expression between groups. DSS and PFS were calcu-
lated using the Kaplan–Meier method by the log-rank test to compare survival outcomes between patient groups 
(low and high expression of marker). The data were expressed as mean with standard deviation (SD) and median 
with quartile (Q1, Q3). All the statistical analyses for the obtained clinical data were performed using SPSS v.22.0 
software (IBM Corp., Armonk, NY, USA) and P-value less than 0.05 was considered as statistically significant.
Ethical approval. This study was approved by the Iran University of Medical Sciences Research Ethics 
Committee (IR.IUMS.REC.1398.1043). All procedures performed in this study were in accordance with the 
1964 Helsinki Declaration and its later amendments. Also, informed consent was obtained from all individual 
participants included in the study at the time of sample collection in accordance with the above-mentioned 
ethical standards.
Data availability
The analyzed data during the current study are available from the corresponding authors on reasonable request.
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